Drug Profile
Research programme: single domain antibodies - Domantis
Alternative Names: DMS 3008Latest Information Update: 19 Apr 2011
Price :
$50
*
At a glance
- Originator Domantis
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Autoimmune disorders; Chronic obstructive pulmonary disease; Hypersensitivity; Inflammation; Inflammatory bowel diseases; Lupus vulgaris; Multiple myeloma; Osteoarthritis; Rheumatoid arthritis; Small cell lung cancer; Solid tumours